Fulgent Genetics, Inc. Investigated by the Portnoy Law Firm

Core Viewpoint - The Portnoy Law Firm has initiated an investigation into potential securities fraud involving Fulgent Genetics, Inc. and may file a class action on behalf of investors [1]. Group 1: Stock Performance and Financial Impact - Fulgent's stock price dropped by $9.43 per share, or 38.09%, closing at $15.33 per share on February 27, 2026, significantly impacting investors [3]. - The decline in stock value was primarily driven by lower-than-expected guidance for 2026, attributed to the Company's largest customer moving a significant volume of work in-house [3]. - This strategic shift by a key partner fundamentally altered Fulgent's projected revenue streams and growth trajectory, leading to a severe erosion of shareholder value [3]. Group 2: Legal Actions and Investor Support - Investors are encouraged to contact attorney Lesley F. Portnoy for legal rights discussions or to join the case, with options for pursuing claims to recover losses [2]. - The Portnoy Law Firm has a history of recovering over $5.5 billion for aggrieved investors, indicating a strong track record in handling corporate wrongdoing cases [4].